Lost Patent Protection? Move To China, Says Specialty Biotech SciClone

The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip